(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 17.43% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.01%.
Neuropace's revenue in 2026 is $94,586,000.On average, 12 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,525,429,158, with the lowest NPCE revenue forecast at $3,342,491,321, and the highest NPCE revenue forecast at $3,657,378,671. On average, 12 Wall Street analysts forecast NPCE's revenue for 2027 to be $4,295,421,748, with the lowest NPCE revenue forecast at $3,903,018,365, and the highest NPCE revenue forecast at $4,529,003,392.
In 2028, NPCE is forecast to generate $5,332,758,520 in revenue, with the lowest revenue forecast at $4,925,885,479 and the highest revenue forecast at $5,659,014,888.